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Background-—Despite higher thromboembolism risk, women with atrial fibrillation have lower oral anticoagulation (OAC) use
compared to men. The influence of the CHA2DS2-VASc score or the introduction of non–vitamin K OACs on this relationship is not
known.
Methods and Results-—Using the PINNACLE National Cardiovascular Data Registry from 2008 to 2014, we compared the
association of sex with OAC use (warfarin or non–vitamin K OACs) overall and by CHA2DS2-VASc score and examined temporal
trends in OAC use by sex. Multivariable regression models assessed the association between sex and OAC use in those with
CHA2DS2-VASc scores ≥2. Temporal analyses assessed changes in OAC use by sex over time. Of the 691 906 atrial fibrillation
patients, 48.5% were women. Women were significantly less likely than men to use any OAC overall (56.7% versus 61.3%; P<0.001)
and at all levels of CHA2DS2-VASc score (adjusted risk ratio 9% to 33% lower, all P<0.001). Compared to other thromboembolic risk
factors, female sex was associated with lower use of OAC (risk ratio 0.90, 95%CI 0.90-0.91). Over time, non–vitamin K OAC use
increased at a slightly higher rate in women (56.2% increase per year, 95%CI 54.6% to 57.9%) compared to men (53.6% increase per
year, 95%CI 52.0% to 55.2%), yet women remained less likely to receive any OAC at all time points (P<0.001).
Conclusions-—Among patients with atrial fibrillation, women were significantly less likely to receive OAC at all levels of the
CHA2DS2-VASc score. Despite increasing non–vitamin K OAC use, women had persistently lower rates of OAC use compared to
men over time. ( J Am Heart Assoc. 2017;6:e005801. DOI: 10.1161/JAHA.117.005801.)
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D espite a higher risk of stroke, women with nonvalvularatrial fibrillation (AF) receive less oral anticoagulation
(OAC) than men.1-10 Possible explanations for decreased OAC
use in women include underrecognition of their higher
thromboembolic risk or concern for bleeding risk on warfarin
in female patients.11,12
Recent advancements in AF care may have addressed
these concerns. First, the CHA2DS2-VASc score for
thromboembolic risk stratification incorporates female sex
as an independent risk factor for thromboembolic events.13
Its incorporation into current AF guidelines may have
increased provider awareness of higher thromboembolic risk
in women and thus increased OAC use.14,15 Second, the
development of non–vitamin K oral anticoagulants (NOAC)
has expanded treatment options for patients with AF. NOACs
have a lower risk of major bleeding and equivalent stroke
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rates compared to warfarin.16-20 Therefore, it is possible that
sex differences in OAC use have diminished with the
introduction of NOACs.
To assess the impact of these advancements on OAC use
in female AF patients, we examined the association of
individual thromboembolic risk factors with OAC use in the
National Cardiovascular Data Registry (NCDR) PINNACLE
Registry of outpatient cardiology practices. Rates of OAC use
were evaluated by sex according to their CHA2DS2-VASc
scores, controlling for estimated bleeding risk. Finally, tem-
poral trends in overall and individual OAC (warfarin and NOAC)
use by sex were assessed. Understanding these relationships
can determine the influence of the CHA2DS2-VASc score and
NOAC use on the sex gap in OAC provision and suggest future
directions for improvement.
Methods
Data Source
The NCDR PINNACLE Registry consists of consecutive
patients from cardiology practices in the United States that
voluntarily participate and submit data as part of a national
office-based cardiovascular quality improvement pro-
gram.21,22 Data are collected at the point of care using a
validated electronic medical record-mapping algorithm for
patients with hypertension (HTN), coronary artery disease,
congestive heart failure, and AF.23,24 Registry data quality is
maintained through data definitions, standard data collection
and transmission, and periodic data quality checks.23-25
Study Population
Between May 1, 2008 and December 31, 2014, 848 931
patients with their first documented AF diagnosis within the
registry were identified. Patients were excluded for missing
data on sex (n=1439, 0.2%), reversible causes of AF (cardiac
surgery, hyperthyroidism, pregnancy, pneumonia; n=1100,
0.1%), other indications for OAC (mechanical heart valve,
valvular heart surgery, systemic embolization; n=6206, 0.7%),
or documented contraindication to OAC (medical reasons or
patient preference; n=24 893, 2.9%), as these would have
impacted decisions to initiate OAC. Patients were excluded if
they had a CHA2DS2-VASc score ≤1 (n=123 387, 14.5%),
leaving a final study cohort of 691 906 patients with high
thromboembolic risk14,15 (Figure 1).
Outcomes
The primary predictor variable for all analyses was patient sex.
The primary outcome was prescription of any OAC defined as
warfarin or NOAC (apixaban, dabigatran, and rivaroxaban)
within 1 year of the patient’s first encounter in the PINNACLE
registry with a diagnosis of AF. Secondary outcomes of
interest were use by OAC class: warfarin or NOACs. For
patients with multiple OAC prescriptions within the first year
of an AF diagnosis, the first prescribed OAC class was used.
Estimation of Thromboembolic Risk
According to practice guidelines, a CHA2DS2-VASc score was
calculated for each patient as the summation of his or her risk
Figure 1. Study cohort. Reversible causes of AF include cardiac
surgery, hyperthyroidism, pregnancy, and pneumonia. Other
indications for OAC include mechanical heart valve or systemic
embolization. Documented contraindications included both med-
ical and patient preferences. AF indicates non-valvular atrial
fibrillation; OAC, oral anticoagulants.
Clinical Perspective
What Is New?
• Women with nonvalvular atrial fibrillation are significantly
less likely to receive oral anticoagulation (warfarin or non–
vitamin K oral anticoagulation) compared to men at all levels
of thromboembolic risk.
• Non–vitamin K oral anticoagulation use has increased in
women at a slightly faster pace than in men, yet women
remained significantly less likely to receive any oral
anticoagulation over time.
What Are the Clinical Implications?
• A risk-treatment paradox for women with atrial fibrillation
exists, suggesting that those at increased thromboembolic
risk are less likely than men to receive guideline-concordant
therapy.
• Underrecognition of female sex as a thromboembolic risk
factor does not fully explain these sex differences and
suggest that clinical guidelines may be applied differently in
women and men.
• Interventions aimed at increasing appropriate oral antico-
agulation use, particularly in women, are needed.
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factor points.13 Risk factors receiving 1 point per factor
included female sex, age 65 to 74 years, history of congestive
heart failure, HTN, diabetes mellitus, or vascular disease. Risk
factors receiving 2 points per factor included age ≥75 years
or a history of prior transient ischemic attack or stroke.13 The
variables included in the CHA2DS2-VASc score were defined
according to NCDR PINNACLE data standards.13,26 Conges-
tive heart failure was defined as symptoms of heart failure or
left ventricular ejection fraction <40%. Vascular disease was
defined by the presence of any of the following: peripheral
arterial disease, peripheral vascular disease, history of
myocardial infarction, prior coronary artery bypass surgery,
percutaneous coronary angioplasty, or percutaneous coronary
intervention.13
Estimation of Bleeding Risk
Bleeding risk was estimated using the modified HAS-BLED
score (mHAS-BLED).27 The mHAS-BLED score is a total of the
patient’s bleeding risk factors including: HTN (diagnosis of
hypertension, or at least 2 prior encounters with systolic
blood pressure ≥140 mm Hg or diastolic blood pressure
≥90 mm Hg within 2 years), abnormal renal function (crea-
tinine ≥2.3 mg/dL), previous stroke, major bleeding history
(intracranial hemorrhage or nonintracranial major hemor-
rhage) or anemia, age ≥65 years, concomitant use of
medications predisposing to bleeding (antiplatelets or nons-
teroidal anti-inflammatory drugs), and alcohol abuse history.
Statistical Analysis
Patient and practice level characteristics were compared
between women and men using chi-squared tests for
categorical variables and Student t test for continuous
variables. Continuous variables were summarized as median
(interquartile range [IQR]) or meanSD, whereas categorical
variables were summarized as percentages and frequencies.
First, the associations of female sex and the other
components of the CHA2DS2-VASc score with OAC use were
examined. Models were adjusted for individual components of
the CHA2DS2-VASc score (congestive heart failure, HTN, age,
etc) and additional patient (race, insurance type [private
versus nonprivate], mHAS-BLED, and rhythm control therapy),
provider (physician versus other provider), and clinic (total
number of physicians at site and proportion of female patients
at site) characteristics. Next, the fully adjusted models were
stratified by CHA2DS2-VASc strata (score=2, 3, 4, 5, and ≥6)
with the individual components of the score removed as
covariates to estimate adjusted risk ratios (RR) by sex within
each CHA2DS2-VASc stratum.
Because of the number of missing variables for estimating
bleeding risk, we conducted a sensitivity analysis excluding
the mHAS-BLED estimate from the multivariable models. The
CHA2DS2-VASc was incorporated into the American Heart
Association/American College of Cardiology/Heart Rhythm
Society guidelines toward the end of the study timeframe
(2014), so we performed a sensitivity analysis stratifying by
the CHADS2 score, which does not include female sex,
vascular disease, or the age category 65 to 74 as risk
factors.28,29
To assess temporal trends in OAC use overall and by class
in women and men, we used multivariable regression with
calendar quarter as a categorical independent variable and
the first quarter of 2010 as our referent group. The cohort
was limited to patients who received an OAC prescription
after 2010 when the Food and Drug Administration approved
the first NOAC (dabigatran). In both women and men we
multiplied the adjusted RR for each quarter by the observed
OAC use for the reference quarter to obtain quarterly risk-
adjusted proportions of patients receiving OAC. A sex-by-
quarter interaction term was included in the models to test
whether the uptake in OAC use differed in women and men.
To examine whether OAC use by sex changed significantly
after guideline updates were published, we examined these
relationships using the quarter prior to publication of the
guidelines as the reference quarter (July to September 2010
for European Society of Cardiology and January to March
2014 for American Heart Association/American College of
Cardiology) and compared rates of OAC use in the subsequent
4 quarters.
All models accounted for clustering of patients by provider
and practice using Generalized Estimating Equations. To
directly estimate RRs, we used the Zou method by specifying
a Poisson distribution and including a robust variance
estimate in our models.30-33
All analyses were performed with SAS version 9.4 (SAS
Institute, Cary, NC). The Harvard Clinical Research Institute
was the primary analytic center for this analysis.
Results
Baseline Characteristics in Women and Men
Our final study cohort included 691 906 patients with AF and
indications for OAC of which 48.5% were women (Figure 1).
Women were older, had lower body mass index, and had a
lower prevalence of coronary artery disease and higher
ejection fraction compared to men. Men had a higher
prevalence of many of the CHA2DS2-VASc risk factors (Table).
The median estimated thromboembolic risk was higher in
women than in men (median CHA2DS2-VASc score 4.0; IQR,
3.0-5.0, versus 3.0; IQR, 2.0-4.0, respectively, P<0.001), and
a larger proportion of women than men were in the higher risk
CHA2DS2-VASc strata (Table). The estimated bleeding risk
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(mHAS-BLED score) was slightly lower in women compared to
men (median score 2; IQR, 2.0-3.0, versus 2; IQR, 2.0-3.0,
P<0.001).
Association of Sex and CHA2DS2-VASc
Components With OAC Use
Overall, 59.1% of the study cohort with an indication for OAC
was prescribed OAC; women were significantly less likely to
receive OAC compared to men (56.7% versus 61.3%, unad-
justed RR 0.92, 95%CI 0.92-0.93) (Figure 2). Among individual
components of CHA2DS2-VASc risk score, female sex and
vascular disease were associated with significantly decreased
OAC prescriptions (adjusted RR 0.90, 95%CI 0.90-0.91 and
RR 0.97, 95%CI 0.96-0.98, respectively). Factors associated
with increased OAC prescription were HTN (RR 1.52, 95%CI
Table. Baseline Characteristics by Sex
Characteristic
Women
(n=335 756)
Men
(n=356 150) P Value
Demographics*
Age*, y 75.411.0 73.910.2 <0.001
Race <0.001
White 64.4% 66.1%
Black 3.4% 2.6%
Asian 0.6% 0.6%
American Indian/
Alaskan Native
0.3% 0.4%
Native
Hawaiian/Pacific
Islander
0.1% 0.1%
Mixed 0.2% 0.2%
Missing 31.1% 30.1%
Insurance <0.001
Private 45.1% 47.6%
Military 2.0% 2.3%
Medicare 60.3% 59.0%
Medicaid 4.1% 2.5%
Other 2.0% 2.1%
None 5.0% 5.4%
Missing 21.4% 21.3%
Clinical characteristics*
CHA2DS2-VASc,
median (IQR)
4.0 (3.0-5.0) 3.0 (2.0-4.0) <0.001
CHA2DS2-VASc
Score
<0.001
2 11.6% 27.5%
3 21.3% 31.5%
4 31.3% 22.5%
5 19.9% 11.6%
6+ 15.8% 6.8%
Thromboembolic risk factors*
CHF 23.3% 30.5% <0.001
Hypertension 80.3% 81.4% <0.001
Age 65 to 74 y 27.7% 33.7% <0.001
Age ≥75 y 57.7% 51.3% <0.001
Diabetes mellitus 20.3% 27.8% <0.001
Ischemic stroke 1.1% 1.2% <0.001
TIA 1.6% 1.6% 0.48
CVA 10.2% 11.3% <0.001
CAD 39.0% 59.9% <0.001
PAD 6.8% 10.6% <0.001
Continued
Table. Continued
Characteristic
Women
(n=335 756)
Men
(n=356 150) P Value
Bleeding risk factors*
mHAS-BLED Score,
median (IQR)
2.0 (2.0-3.0) 2.0 (2.0-3.0) <0.001
Renal dysfunction 0.3% 0.5% <0.001
Bleeding history 1.4% 1.6% <0.001
Antiplatelet or NSAID
drug use
51.4% 59.9% <0.001
Age ≥65 y 85.4% 83.1% <0.001
Heavy ETOH use 0.1% 0.3% <0.001
Hemorrhagic stroke 0.09% 0.12% <0.001
Intracranial hemorrhage 1.1% 1.3% <0.001
Vascular complications 0.8% 1.1% <0.001
Other clinical characteristics*
BMI 28.96.9 29.75.8 <0.001
LVEF 57.412.1 50.913.9 <0.001
Hyperlipidemia 55.3% 65.9% <0.001
History of tobacco use 46.7% 66.4% <0.001
Practice site variables*
Practice size (number
of providers)
25.119.5 24.719.1 <0.001
Provider type <0.001
Physician 89.4% 89.8%
Other 10.6% 10.2%
BMI indicates body mass index; CAD, coronary artery disease; CHF, congestive heart
failure; CVA, cerebrovascular attack; Heavy ETOH, alcohol use defined at >8 drinks/day;
IQR, interquartile range; LVEF, left ventricular ejection fraction; NSAID, nonsteroidal anti-
inflammatory medication; PAD, peripheral arterial disease; TIA, transient ischemic attack.
*Continuous variables reported as meanSD, except where noted as Median (IQR), all
categorical variables presented as percentage.
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1.50-1.54), age 65 to 74 (RR 1.68, 95%CI 1.66-1.71), and age
≥75 years (RR 1.70, 95%CI 1.67-1.72) (Figure 3).
OAC Use in Women and Men by CHA2DS2-VASc
Score
In analysis stratified by CHA2DS2-VASc score, women had
significantly lower rates of OAC use compared to men at all
strata (adjusted RR 9% to 33% lower, all P<0.001) (Figure 4).
For example, in the fully adjusted models, women with a
CHA2DS2-VASc score=5 were 12% less likely to have OAC
prescribed than men with CHA2DS2-VASc score=5 (adjusted
RR 0.88, 95%CI 0.87-0.89). In sensitivity analysis these
relationships persisted when stratifying by the CHADS2 score
(Figure 5). Similarly, removal of the mHAS-BLED score from
the multivariable models did not significantly change the
results (not shown).
Temporal Trends in OAC Use
Over the study, there was a similar increase in overall OAC
use in both women and men (women 3.0% increase per year,
95%CI 2.5% to 3.5%; and men 2.8% increase per year, 95%CI
2.3% to 3.3%; P-value for time-by-sex interaction 0.12)
(Figure 6). Women remained significantly less likely to receive
any OAC compared to men at all time points (all P<0.001).
There was no significant change in overall OAC use after
adoption of CHA2DS2-VASc into European Society of Cardi-
ology or American Heart Association/American College of
Cardiology guidelines (all P>0.05).
Beginning in 2010, NOAC use increased at a slightly higher
rate in women (56.2% increase per year, 95%CI 54.6% to
57.9%) compared to men (53.6% increase per year, 95%CI
52.0% to 55.2%; P-value for time-by-sex interaction <0.001)
(Figure 6). By the second quarter of 2014, NOAC use
surpassed the use of warfarin in both women and men. Over
the same timeframe, warfarin use declined at a slightly higher
rate in women (14.4% decrease per year, 95%CI 13.8% to 15%)
compared to men (13.8% decrease per year, 95%CI 13.1% to
14.4%; P-value for time by sex interaction 0.003).
Discussion
In this contemporary cohort of US patients with AF and
indications for OAC, female sex was associated with signif-
icantly less OAC use compared to male sex across the
spectrum of thromboembolic risk. Over the past decade, OAC
use has gradually increased each year for both women and
men. Warfarin use has been declining and NOAC use
increasing; these changes have been slightly more pro-
nounced in women compared to men. Even with these shifts
in therapy type, women remained significantly less likely than
Figure 2. Unadjusted rates of oral anticoagulant use for nonvalvular atrial fibrillation in women and men
by CHA2DS2-VASc Score. OAC indicates oral anticoagulants.
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men to receive OAC at all time points. Despite the introduc-
tion of the CHA2DS2-VASc score and NOACs, a risk treatment
paradox for OAC use in eligible women with AF persists.
Our study suggests that female sex is underemphasized as
a thromboembolic risk factor. Compared to other throm-
boembolic risk factors in the CHA2DS2-VASc score (ie, HTN or
age), female sex was associated with relatively lower use of
OAC. Further, women were significantly less likely than men
to receive guideline-concordant OAC at all levels of estimated
thromboembolic risk. In the CHA2DS2-VASc scoring system,
women previously viewed as intermediate risk (CHADS2=1)
are now categorized as high risk (CHA2DS2-VASc 2 or
more).34-36 In our study, differences in OAC use were most
pronounced in lower CHA2DS2-VASc scores (ie, CHA2DS2-
VASc=2), which suggests that female sex as a thromboem-
bolic risk factor has less weight on OAC use compared to
other factors. However, in our sensitivity analysis stratified by
CHADS2 scores (sex not included as an independent risk
factor), we found lower rates of OAC use in women across the
spectrum of estimated thromboembolic risk. Taken together,
women were consistently less likely to receive OAC compared
to men independent of level or method of estimating
thromboembolic risk. Therefore, our findings suggest factors
beyond thromboembolic risk alone contribute to lower rates
of OAC use in women.
We also examined whether expanded treatment options,
specifically NOACs, have affected sex differences in OAC use
over time. Compared to warfarin therapy, NOAC therapy
offers potential benefits including standardized dosing regi-
mens, lack of intensive laboratory monitoring, and lower rates
of major bleeding.17,37 Our findings suggest that sex differ-
ences in OAC use may be primarily due to differences in the
Decreased OAC Use
CHA2DS2-VASc 
Component
Female
Hypertension
Age 65-74
Age ≥ 75
Diabetes Mellitus
Vascular Disease
Stroke/TIA
Risk Ratio, 95% CI
0.90 (0.90, 0.91)
1.12 (1.11, 1.12)
Increased OAC Use
1.52 (1.50, 1.54)
1.68 (1.66, 1.71)
1.70 (1.67, 1.72)
0.97 (0.96, 0.98)
1.44 (1.42, 1.46)
1.0
CHF
1.08 (1.08, 1.09)
All P <0.001
0.9 1.5
Figure 3. Adjusted association between individual CHA2DS2-
VASc factors and OAC use among those with CHA2DS2-VASc ≥2.
Analyses were adjusted for other CHA2DS2-VASc variables and
race, insurance (private vs nonprivate), mHAS-BLED score, rhythm
control therapy, total number of physicians at site, provider type
(physician vs other provider), proportion of female patients at site,
and clustering by practice and provider. CHF indicates congestive
heart failure; OAC, oral anticoagulant; TIA, transient ischemic
attack. Vascular Disease indicates peripheral vascular disease,
history of myocardial infarction, prior coronary artery bypass, or
prior percutaneous coronary intervention.
CHA2DS2-VASc
Score
Risk Ratio, 95% CI
(F vs M)
2
3
4
5
≥6
0.67, 0.66-0.68
1.0Less Use in Women Greater Use in Women
0.82, 0.81-0.82
0.90, 0.90-0.91
0.88, 0.87-0.89
0.91, 0.90-0.92
0.6
<0.001
P-value
<0.001
<0.001
<0.001
<0.001
Figure 4. Adjusted rates of oral anticoagulant use for nonva-
lvular atrial fibrillation in women and men stratified by CHA2DS2-
VASc score. Analyses were adjusted for race, insurance type
(private vs nonprivate), modified HAS-BLED score, rhythm control
therapy, number of physicians at site, number of physician vs
other providers, proportion of female patients at site, and
clustering by practice and provider. P value for sex CHA2DS2-
VASc interaction < 0.001.
Figure 5. Adjusted rates of oral anticoagulant use for
nonvalvular atrial fibrillation in women and men stratified by
CHADS2 score. Analyses adjusted for race, insurance (private
vs nonprivate), mHAS-BLED score, rhythm control therapy,
total number of physicians at site, provider type (physician vs
other provider), proportion of female patients at site. P value
for sex9CHADS2 interaction <0.001.
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use of warfarin. Over the past 5 years, warfarin use has
gradually decreased, and NOAC use has increased by as much
as 50% per year in both women and men with a slightly
greater rate of increase for women. Prior studies assessing
sex differences in OAC have been unable to assess the impact
of NOACs by sex due to low rates of NOAC use.38-40 As of
2014, 1 in 3 people with AF were prescribed a NOAC,
representing >50% of those receiving some form of OAC for
AF. Therefore, it is possible that if NOAC use continues to
increase over time, sex differences in overall OAC use may
decrease and eventually be eliminated.
Our findings differ from other AF specific registries that
found no significant sex differences in OAC use.38-40 The
ORBIT (Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation), EORP (Euro Observational Research Pro-
gram), and GARFIELD (Global Anticoagulant Registry in the
FIELD-Atrial Fibrillation) registries prospectively enroll
patients based on specific inclusion and exclusion criteria,
introducing the possibility of selection bias. In contrast,
PINNACLE is a quality-improvement program that captures
data on all patients with a diagnosis of AF and may more
closely reflect broad clinical practice. Another important
difference between our study and the GARFIELD and EORP
registries is that these studies were largely international
cohorts. European Society of Cardiology guidelines included
the CHA2DS2-VASc score in 2010, whereas the American
Heart Association/American College of Cardiology guidelines
included the score in 2014.14,15 Earlier diffusion of evidence
in these countries supporting female sex as an independent
risk factor for thromboembolic events may contribute to these
differences.
In contemporary general US cardiology practices, our study
provides evidence for sex differences in OAC use among
eligible patients with AF that are independent of thromboem-
bolic risk and the introduction of NOACs. A potential reason
for these observed sex differences might be differences in
patient or provider preferences. For example, women may be
more likely to decline OAC therapy, particularly warfarin, due
to concerns for bleeding, inconvenience, or lack of social
support (ie, transportation for international normalized ratio
check).9 Additionally, providers may perceive increased frailty
or bleeding risk in women compared to men because women
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Year by Quarter
Male Overall OAC Use
Female Overall OAC Use
Male Warfarin Use
Female Warfarin Use
Male NOAC Use
Female NOAC Use
Male: 2.8% Increase Overall OAC Use Per Year
Female: 3.0% Increase Overall OAC Use Per Year
Male: 13.8% Decrease Warfarin Use Per Year
Female: 14.4% Decrease Warfarin Use Per Year
Male: 53.6% Increase NOAC Use Per Year
Female: 56.2% Increase NOAC Use Per Year
P for all trends <0.001
Figure 6. Trends in oral anticoagulant use from 2010 to 2014 by anticoagulant type in women and men.
There was no significant change in OAC use for women or men following introduction of European Society
of Cardiology guidelines in 2010 or American Heart Association/American College of Cardiology guidelines
in 2014 (all P<0.05). Analyses were adjusted for: race, insurance type (private vs nonprivate), CHA2DS2-
VASc score, modified HAS-BLED score, rhythm control therapy, total number of physicians at site, provider
type (physician vs other provider), proportion of female subjects at site, and clustering by provider and
practice. NOAC indicates non–vitamin K oral anticoagulant; OAC, oral anticoagulant.
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have been shown to have higher rates of bleeding while on
warfarin and after cardiac interventions.6,11,16,41-43 Our find-
ing of greater increases in NOAC use in women compared to
men may support the notion that higher bleeding risk
contributed to past sex differences in OAC use when therapy
options were more limited. However, in our study, sex
differences persisted across our entire study timeframe after
controlling for estimated bleeding risk and allowing for the
introduction of NOACs. Finally, US cardiologists may apply
clinical guidelines at lower rates in women compared to men,
suggesting a bias in how care is delivered.44-46 Future studies
should examine these potential causes in order to understand
and work to eliminate sex differences in OAC use.
Certain limitations must be considered when interpreting
our study. First, whether the demonstrated statistically
significant differences in OAC use correspond to clinically
significant differences in patient outcomes was not investi-
gated and warrants further evaluation. However, prior studies
have demonstrated that sex-related differences in the risk of
stroke decrease when OAC are used.9 Also, sex differences
were observed at the highest level of estimated thromboem-
bolic risk (CHA2DS2-VASc ≥6), suggesting that even small
absolute differences in OAC use may translate into significant
sex differences in clinical outcomes. Second, we were unable
to determine whether all potential contraindications or
provider or patient preferences regarding OAC use potentially
differed by patient sex. However, we excluded patients with a
documented contraindication for OAC use, either for personal
preference or medical reasons, and we saw no sex differences
in this exclusion (49.5% female versus 50.5% male, P>0.05).
Third, the CHA2DS2-VASc score was only incorporated into US
clinical guidelines in 2014; thus, many clinicians in the United
States may not have been using the CHA2DS2-VASc score for
risk stratification during the cohort period. However, our
findings were unchanged in sensitivity analysis stratified by
CHADS2 score, the previous guideline-recommended risk
stratification tool. Finally, reported OAC use may be lower
than actual use due to underreporting in the PINNACLE
registry. We would not expect underreporting to occur
differentially according to patient sex. Further, we allowed
1 year of follow-up for OAC use to be documented, increasing
capture of OAC use, and our observed rates of OAC use were
similar to what has been seen in previous clinical
cohorts.40,47,48
Conclusions
In this contemporary cohort of cardiology patients in the
United States with AF and indications for anticoagulation,
women were 9% to 33% less likely than men to receive OAC
at all levels of thromboembolic risk. Despite the introduction
of NOACs and their rapidly increased use over time, women
remained significantly less likely to receive OAC at all time
points. Underrecognition of female sex as a thromboembolic
risk factor does not fully explain these differences, suggest-
ing that clinical guidelines may be applied differently in
women and men. Further studies are needed to understand
whether lower rates of OAC use in women are associated
with differences in clinical outcomes, and if so, action is
needed to eliminate unnecessary differences in OAC use by
sex.
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